Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia
- 1 September 2009
- journal article
- clinical trial
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 94 (9), 1266-1273
- https://doi.org/10.3324/haematol.2009.005835
Abstract
Background In chronic lymphocytic leukemia lenalidomide causes striking immune activation, possibly leading to clearance of tumor cells. We conducted this study to investigate the mechanism of action of lenalidomide and the basis for its unique toxicities in chronic lymphocytic leukemia. Design and Methods Patients with relapsed chronic lymphocytic leukemia were treated with lenalidomide 20 mg (n=10) or 10 mg (n=8) daily for 3 weeks on a 6-week cycle. Correlative studies assessed expression of co-stimulatory molecules on tumor cells, T-cell activation, cytokine levels, and changes in lymphocyte subsets. Results Lenalidomide upregulated the co-stimulatory molecule CD80 on chronic lymphocytic leukemia and mantle cell lymphoma cells but not on normal peripheral blood B cells in vitro. T-cell activation was apparent in chronic lymphocytic leukemia, weak in mantle cell lymphoma, but absent in normal peripheral blood mononuclear cells and correlated with the upregulation of CD80 on B cells. Strong CD80 upregulation and T-cell activation predicted more severe side effects, manifesting in 83% of patients as a cytokine release syndrome within 8–72 h after the first dose of lenalidomide. Serum levels of various cytokines, including tumor necrosis factor-α, increased during treatment. CD80 upregulation on tumor cells correlated with rapid clearance of leukemic cells from the peripheral blood. In contrast, neither the severity of the cytokine release syndrome nor the degree of T-cell activation in vitro correlated with clinical response. Conclusions Upregulation of CD80 on tumor cells and T-cell activation correlate with unique toxicities of lenalidomide in chronic lymphocytic leukemia. However, T-cell activation appears to be dispensable for the drug’s anti-tumor effects. This provides a rationale for combinations of lenalidomide with fludarabine or alemtuzumab.Keywords
This publication has 19 references indexed in Scilit:
- Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2008
- Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drugJCI Insight, 2008
- Lenalidomide for the Treatment of B-Cell MalignanciesJournal of Clinical Oncology, 2008
- Tumor Lysis Syndrome/Tumor Flare Reaction in Lenalidomide-Treated Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2007
- Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's LymphomaClinical Cancer Research, 2007
- Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II StudyJournal of Clinical Oncology, 2006
- A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaBlood, 2006
- Phase I to II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Patients With Advanced Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2005
- B-Cell Lymphomas Differ in their Responsiveness to CpG OligodeoxynucleotidesClinical Cancer Research, 2005
- Distinct Role of CD80 and CD86 in the Regulation of the Activation of B Cell and B Cell LymphomaJournal of Biological Chemistry, 2002